BACKGROUND: Gene fusions represent promising targets for cancer therapy in lung cancer. Reliable detection of multiple gene fusions is therefore essential. METHODS: Five commercially available parallel sequencing assays were evaluated for their ability to detect gene fusions in eight cell lines and 18 FFPE tissue samples carrying a variety of known gene fusions. Four RNA-based assays and one DNA-based assay were compared; two were hybrid capture-based, TruSight Tumor 170 Assay (Illumina) and SureSelect XT HS Custom Panel (Agilent), and three were amplicon-based, Archer FusionPlex Lung Panel (ArcherDX), QIAseq RNAscan Custom Panel (Qiagen) and Oncomine Focus Assay (Thermo Fisher Scientific). RESULTS: The Illumina assay detected all tested fusions and showed the smallest number of false positive results. Both, the ArcherDX and Qiagen panels missed only one fusion event. Among the RNA-based assays, the Qiagen panel had the highest number of false positive events. The Oncomine Focus Assay (Thermo Fisher Scientific) was the least adequate assay for our purposes, seven fusions were not covered by the assay and two fusions were classified as uncertain. The DNA-based SureSelect XT HS Custom Panel (Agilent) missed three fusions and nine fusions were only called by one software version. Additionally, many false positive fusions were observed. CONCLUSIONS: In summary, especially RNA-based parallel sequencing approaches are potent tools for reliable detection of targetable gene fusions in clinical diagnostics.
BACKGROUND: Gene fusions represent promising targets for cancer therapy in lung cancer. Reliable detection of multiple gene fusions is therefore essential. METHODS: Five commercially available parallel sequencing assays were evaluated for their ability to detect gene fusions in eight cell lines and 18 FFPE tissue samples carrying a variety of known gene fusions. Four RNA-based assays and one DNA-based assay were compared; two were hybrid capture-based, TruSight Tumor 170 Assay (Illumina) and SureSelect XT HS Custom Panel (Agilent), and three were amplicon-based, Archer FusionPlex Lung Panel (ArcherDX), QIAseq RNAscan Custom Panel (Qiagen) and Oncomine Focus Assay (Thermo Fisher Scientific). RESULTS: The Illumina assay detected all tested fusions and showed the smallest number of false positive results. Both, the ArcherDX and Qiagen panels missed only one fusion event. Among the RNA-based assays, the Qiagen panel had the highest number of false positive events. The Oncomine Focus Assay (Thermo Fisher Scientific) was the least adequate assay for our purposes, seven fusions were not covered by the assay and two fusions were classified as uncertain. The DNA-based SureSelect XT HS Custom Panel (Agilent) missed three fusions and nine fusions were only called by one software version. Additionally, many false positive fusions were observed. CONCLUSIONS: In summary, especially RNA-based parallel sequencing approaches are potent tools for reliable detection of targetable gene fusions in clinical diagnostics.
Authors: Kurtis D Davies; Terry L Ng; Adriana Estrada-Bernal; Anh T Le; Peter R Ennever; D Ross Camidge; Robert C Doebele; Dara L Aisner Journal: JCO Precis Oncol Date: 2017-08-29
Authors: Justin F Gainor; Anna M Varghese; Sai-Hong Ignatius Ou; Sheheryar Kabraji; Mark M Awad; Ryohei Katayama; Amanda Pawlak; Mari Mino-Kenudson; Beow Y Yeap; Gregory J Riely; A John Iafrate; Maria E Arcila; Marc Ladanyi; Jeffrey A Engelman; Dora Dias-Santagata; Alice T Shaw Journal: Clin Cancer Res Date: 2013-05-31 Impact factor: 12.531
Authors: Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb Journal: Cell Date: 2007-12-14 Impact factor: 41.582
Authors: Joshua D Campbell; Anton Alexandrov; Jaegil Kim; Jeremiah Wala; Alice H Berger; Chandra Sekhar Pedamallu; Sachet A Shukla; Guangwu Guo; Angela N Brooks; Bradley A Murray; Marcin Imielinski; Xin Hu; Shiyun Ling; Rehan Akbani; Mara Rosenberg; Carrie Cibulskis; Aruna Ramachandran; Eric A Collisson; David J Kwiatkowski; Michael S Lawrence; John N Weinstein; Roel G W Verhaak; Catherine J Wu; Peter S Hammerman; Andrew D Cherniack; Gad Getz; Maxim N Artyomov; Robert Schreiber; Ramaswamy Govindan; Matthew Meyerson Journal: Nat Genet Date: 2016-05-09 Impact factor: 38.330
Authors: Brian C Haynes; Richard A Blidner; Robyn D Cardwell; Robert Zeigler; Shobha Gokul; Julie R Thibert; Liangjing Chen; Junya Fujimoto; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba; Gary J Latham Journal: Transl Oncol Date: 2019-04-12 Impact factor: 4.243
Authors: Sarah Walters; Camille Maringe; Michel P Coleman; Michael D Peake; John Butler; Nicholas Young; Stefan Bergström; Louise Hanna; Erik Jakobsen; Karl Kölbeck; Stein Sundstrøm; Gerda Engholm; Anna Gavin; Marianne L Gjerstorff; Juanita Hatcher; Tom Børge Johannesen; Karen M Linklater; Colleen E McGahan; John Steward; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet Journal: Thorax Date: 2013-02-11 Impact factor: 9.139
Authors: Alexander Drilon; Jeffrey W Clark; Jared Weiss; Sai-Hong Ignatius Ou; D Ross Camidge; Benjamin J Solomon; Gregory A Otterson; Liza C Villaruz; Gregory J Riely; Rebecca S Heist; Mark M Awad; Geoffrey I Shapiro; Miyako Satouchi; Toyoaki Hida; Hidetoshi Hayashi; Danielle A Murphy; Sherry C Wang; Sherry Li; Tiziana Usari; Keith D Wilner; Paul K Paik Journal: Nat Med Date: 2020-01-13 Impact factor: 53.440
Authors: Shinkyo Yoon; Miso Kim; Yong Sang Hong; Han Sang Kim; Seung Tae Kim; Jihun Kim; Hongseok Yun; Changhoon Yoo; Hee Kyung Ahn; Hyo Song Kim; In Hee Lee; In-Ho Kim; Inkeun Park; Jae Ho Jeong; Jaekyung Cheon; Jin Won Kim; Jina Yun; Sun Min Lim; Yongjun Cha; Se Jin Jang; Dae Young Zang; Tae Won Kim; Jin Hyoung Kang; Jee Hyun Kim Journal: Cancer Res Treat Date: 2021-12-13 Impact factor: 4.679
Authors: Jayne Y Hehir-Kwa; Marco J Koudijs; Eugene T P Verwiel; Lennart A Kester; Marc van Tuil; Eric Strengman; Arjan Buijs; Mariëtte E G Kranendonk; Laura S Hiemcke-Jiwa; Valerie de Haas; Ellen van de Geer; Wendy de Leng; Jasper van der Lugt; Philip Lijnzaad; Frank C P Holstege; Patrick Kemmeren; Bastiaan B J Tops Journal: JCO Precis Oncol Date: 2022-01
Authors: Giuseppe Broggi; Eliana Piombino; Roberto Altieri; Chiara Romano; Francesco Certo; Giuseppe Maria Vincenzo Barbagallo; Paolo Vigneri; Dario Condorelli; Lorenzo Colarossi; Cristina Colarossi; Gaetano Magro; Elena Tirrò Journal: Front Neurol Date: 2022-02-09 Impact factor: 4.003